RATIONALE: Learning how often patients experience nausea and vomiting after receiving
anti-vomiting medicine and chemotherapy for colorectal cancer may help doctors plan better
treatment and improve patients' quality of life.
PURPOSE: This clinical trial is studying delayed nausea and vomiting in patients with
colorectal cancer receiving standard anti-vomiting medicine during the first course of
- To assess the prevalence of delayed nausea and vomiting in patients with colorectal
cancer receiving standard anti-emetic medications during the first course of an
oxaliplatin-based chemotherapy regimen (mFOLFOX6 or FOLFOX7).
OUTLINE: This is a multicenter study.
Patients undergo collection of demographic, diagnostic, and treatment data at baseline.
Patients complete the Functional Living Index-Emesis (FLIE) questionnaire at baseline prior
to first chemotherapy infusion and at 5-7 days. Patients also fill out daily patient diaries
about symptoms of nausea and vomiting, and use of medications to prevent these symptoms over
- Diagnosis of colorectal cancer
- Currently receiving OR scheduled to receive the first course of either of the
following chemotherapy regimens:
- No clinical or imaging evidence of brain metastasis
- Able to maintain a diary and complete a standardized quality of life questionnaire in
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 90 days since prior aprepitant